Clozapine Beta blockers

Drugs that may be affected by SSRIs Drugs that may be affected by SSRIs include alcohol, benzodiazepines, beta blockers, buspirone, carbamazepine, cisapride, clozapine, cyclosporine, diltiazem, digoxin, haloperidol, hydantoins, lithium, methadone, mexiletine, nonsedating antihistamines, NSAIDs, olanzapine, phenothiazines, phenytoin, pimozide, procyclidine, ritonavir, ropivacaine, sumatriptan, sulfonylureas, sympathomimetics, tacrine, theophylline, tolbutamide, tricyclic antidepressants, and warfarin. 

IMATINIB 1. ANTIARRHYTHMICS -flecainide, mexiletine, propafenone 2. ANTIDEPRESSANTS - fluoxetine, paroxetine, TCAs, trazodone, venlafaxine 3. ANTIPSYCHOTICS -clozapine, haloperidol, perphenazine, risperidone, thioridazine 4. BETA-BLOCKERS - metoprolol, propanolol, timolol 5. DONEPEZIL 6. METHAMPHETAMINE Imatinib may cause t plasma concentrations of these drugs, with a risk of toxic effects Inhibition of CYP2D6-mediated metabolism of these drugs Watch for early features of toxicity of these drugs... 

Minocycline Penicillamine Beta-blockers (e.g., propanolol, pindolol, atenolol, metoprolol, timolol) Hydrochlorothiazide Interferon-a Fluorouracil agents hydroxyurea, interferons, gemfibrozil, interleukin-2, clobazam, clozapine, tocainide, lisinopril, etanercept, infliximab, zafirlukast... 

Metabolic Hypertriglyceridemia Beta-blockers, clomiphene, corticosteroids, dibenzodiazepine-derived atypical antipsychotics (clozapine, olanzapine, and quetiapine), estrogens, furosemide, isotretinoin, propofol, protease inhibitors, retinoid derivatives, tamoxifen, thiazides... 

Clozapine Bupropion eyelophosphamide Paelitaxel NSAIDs Dielofenae PPls Lansoprazole Beta-blockers Anesthetics Enflurane Macrolide antibiotics... 

Selertive serotonin reuptake inhibitors may decrease metabolism of alpha/beta blockers, benzodiazepines, carbamazepine, cimetidine, clozapine, fesoterodine, haloperidol, methadone, mexiletine, phenytoin, propafenone, respiradone, tamoxifen, galantamine, respiradone, thioridazine. 

A systematic review (11 trials) evaluated the risk of extrapyramidal side effects in first-episode psychosis [39 ]. Halo-peridol was significantly associated with higher rates/severity of Parkinsonism and akathisia, worse extrapyramidal outcomes and greater use of anticholinergics and beta-blockers compared with SGAs there was also a higher dyskinesia in two of four trials. Extrapyramidal symptoms were decreased for clozapine versus chlorpromazine and for risperidone versus zuclopenthixol. 

Smoking cessation, with or without nicotine substitutes, may alter response to concomitant medication in ex-smokers. Smoking may affect alcohol, benzodiazepines, beta-adrenergic blockers, caffeine, clozapine, fluvoxamine, olanzapine, tacrine, theophylline, clorazepate, lidocaine (oral), estradiol, flecanide, imipramine, heparin, insulin, mexiletine, opioids, propranolol, catecholamines, and cortisol. 

NSAID and warfarin ACE inhibitors and K-sparing dinretic Verapamil and beta-adrenergic antagonists Nenromnscnlar (NM) blockers and aminoglycosides Alcohol and benzodiazpines Thioridazine and halofantrine Clozapine and co-trimoxazole Increased risk of bleeding Increased risk of hyperkalaemia Bradycardia and asystole Increased NM blockade Increased sedation Increased risk of QT interval prolongation Increased risk of bone marrow suppression... 

PET scans of the brain of untreated schizophrenics have revealed small increases in dopamine receptors. Dopamine receptor blockers should be avoided in parkinsonism. While most conventional antipsychotic drugs block receptors, this action is not an absolute requirement for antipsychotic action, since clozapine and newer drugs have a very low affinity for such receptors. The clinical potency of antipsychotic drugs does not correlate well with their beta adrenoceptorblocking actions. The effects of phencyclidine (PCP) closely parallel an acute schizophrenic episode, but PCP has no actions on brain dopamine receptors. The answer is (D). 

---